Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cholangiocarcinoma × Immunotherapy × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Lung Diseases 1 Esophageal Squamous Cell Carcinoma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Solid Tumor 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Gemcitabine 7 pembrolizumab 6 Cisplatin 4 durvalumab 3 Oxaliplatin 3 Nivolumab 3 fludarabine 2 Ipilimumab 2 Drug Therapy 2 Cyclophosphamide 2 Capecitabine 2 130-nm albumin-bound paclitaxel 2 tremelimumab 1 trametinib 1 tivozanib 1 tislelizumab 1 silmitasertib 1 pertuzumab 1 olutasidenib 1 lenvatinib 1 enasidenib 1 devimistat 1 derazantinib 1 atezolizumab 1 aldesleukin 1 Specimen Handling 1 Sorafenib 1 Ritonavir 1 Radiation 1 Magnetic Resonance Spectroscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡